Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 3
1946 3
1947 2
1948 1
1949 1
1952 4
1953 3
1954 4
1955 2
1956 6
1957 4
1958 4
1959 1
1960 3
1961 2
1962 4
1963 4
1964 5
1965 6
1966 5
1967 9
1968 17
1969 9
1970 7
1971 15
1972 14
1973 10
1974 11
1975 18
1976 30
1977 23
1978 29
1979 26
1980 11
1981 13
1982 14
1983 14
1984 12
1985 23
1986 19
1987 19
1988 25
1989 16
1990 18
1991 14
1992 12
1993 15
1994 22
1995 15
1996 16
1997 17
1998 20
1999 23
2000 19
2001 18
2002 15
2003 15
2004 12
2005 24
2006 29
2007 19
2008 37
2009 28
2010 24
2011 26
2012 24
2013 22
2014 23
2015 21
2016 25
2017 35
2018 33
2019 27
2020 24
2021 27
2022 15
2023 18
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

1,114 results

Results by year

Filters applied: . Clear all
Page 1
Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study.
Schjesvold FH, Ludwig H, Delimpasi S, Robak P, Coriu D, Tomczak W, Pour L, Spicka I, Dimopoulos MA, Masszi T, Chernova NG, Sandberg A, Thuresson M, Norin S, Bakker NA, Mateos MV, Richardson PG, Sonneveld P. Schjesvold FH, et al. Among authors: ludwig h. Haematologica. 2024 Feb 29. doi: 10.3324/haematol.2023.284635. Online ahead of print. Haematologica. 2024. PMID: 38426292 Free article.
Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma.
Ludwig H, Melchardt T, Sormann S, Schreder M, Andel J, Hartmann B, Tinchon C, Zojer N, Gunsilius E, Podar K, Egle A, Willenbacher W, Wöll E, Ruckser R, Bozic B, Krauth MT, Petzer A, Schmitt C, Machherndl-Spandl S, Agis H, Fillitz M, Wang SY, Zabernigg A, Knop S, Paiva B, Greil R. Ludwig H, et al. Am J Hematol. 2024 May;99(5):1008-1011. doi: 10.1002/ajh.27280. Epub 2024 Feb 29. Am J Hematol. 2024. PMID: 38425185 Clinical Trial.
Potential Predictors for Deterioration of Renal Function After Transfusion.
Tschoellitsch T, Moser P, Maletzky A, Seidl P, Böck C, Roland T, Ludwig H, Süssner S, Hochreiter S, Meier J. Tschoellitsch T, et al. Among authors: ludwig h. Anesth Analg. 2024 Mar 1;138(3):645-654. doi: 10.1213/ANE.0000000000006720. Epub 2024 Feb 16. Anesth Analg. 2024. PMID: 38364244
Update and European consensus on a patient-centered core outcome set for multiple myeloma in clinical practice and research.
Oerlemans S, De Rooij BH, Bennink C, Bullinger L, Broijl A, D'Agostino M, Laane E, Lupo-Stanghellini MT, Perrot A, Wester R, Cursaru V, Scheurer H, Vesseur J, Dalal M, Sen R, Stamm T, Ludwig H, Sonneveld P. Oerlemans S, et al. Among authors: ludwig h. Haematologica. 2024 Feb 1. doi: 10.3324/haematol.2023.284282. Online ahead of print. Haematologica. 2024. PMID: 38299690 Free article.
Use Via Early Access to Ixazomib (UVEA-IXA) Study: Effectiveness and Safety of Ixazomib-based Therapy in Relapsed/Refractory Multiple Myeloma Outside of the Clinical Trial Setting.
Ludwig H, Ramasamy K, Mateos MV, Kishore B, Gergely V, Ladicka M, Ori A, Simoni L, Bent-Ennakhil N, Stull DM, Gavini F, Terpos E, Hájek R. Ludwig H, et al. Clin Lymphoma Myeloma Leuk. 2024 Feb;24(2):e40-e49.e3. doi: 10.1016/j.clml.2023.10.003. Epub 2023 Oct 14. Clin Lymphoma Myeloma Leuk. 2024. PMID: 37996265 Free article.
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel.
Raje N, Anderson K, Einsele H, Efebera Y, Gay F, Hammond SP, Lesokhin AM, Lonial S, Ludwig H, Moreau P, Patel K, Ramasamy K, Mateos MV. Raje N, et al. Among authors: ludwig h. Blood Cancer J. 2023 Aug 1;13(1):116. doi: 10.1038/s41408-023-00879-7. Blood Cancer J. 2023. PMID: 37528088 Free PMC article. Review.
1,114 results